About Delfi Diagnostics Inc.
What Delfi Diagnostics Inc. is building
Technologies used at Delfi Diagnostics Inc.
C++
Java
C#
GitCompany culture
Lead With Science, Anchored in Pragmatism
We pioneer life-changing science by ensuring quality, transparency, and rigor at all times.
Build With and For All
We are not just building a product—we aim to disrupt the path of cancer for all, regardless of geography or socioeconomic class.
Funding rounds
Total Funding
Last funding round type
Company type
Delfi Diagnostics Inc. news and updates
Delfi Diagnostics hires Paul Sheives as Vice President of Government Relations and Reimbursement
Michaela Hart has joined as Delfi's Vice President of Regulatory, Quality and Lab Operations, and Paul Sheives has joined as Vice President of Government Relations and Reimbursement.
Jan 1, 2022 | wfmz.comDelfi Diagnostics hires Liz Homans as board of directors
Delfi Diagnostics has appointed Liz Homans to its board of directors.
Jan 1, 2022 | genomeweb.comDelfi Diagnostics hires Jacob Van Naarden as board of directors
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection and monitoring, appointed Jacob Van Naarden, Senior Vice President of Eli Lilly and Company and CEO of Loxo@Lilly, to its board of directors.
Jan 1, 2022 | prnewswire.comDelfi Diagnostics partners with MSK
As for latest updates on liquid biopsy, Delfi Diagnostics entered into a research agreement with Memorial Sloan Kettering Cancer Center to further develop its liquid biopsy platform and translating it into clinics.
Jan 1, 2022 | art25capital.comDelfi Diagnostics hires Jessica Meng as Chief Commercial Officer
Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company's first Chief Commercial Officer.
Jan 1, 2022 | prnewswire.comDelfi Diagnostics receives financing of $225M in Series B funding
Delfi Diagnostics, Inc., a Palo Alto, CA- and Baltimore, MD-based developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, raised USD225m in Series B funding.
Jan 1, 2022 | finsmes.comDFJ Growth invests into Delfi Diagnostics in $225M
Delfi Diagnostics, a US-based developer of liquid biopsy tests for early cancer detection, has received US$225m in a Series B financing round led by venture capital firm DFJ Growth.
Jan 1, 2022 | healthcareafrica.infoDelfi Diagnostics is developing liquid biopsy test
Delfi Diagnostics has raised $225 million in a series B round to develop its liquid biopsy test.
Jan 1, 2022 | mddionline.comDoug Schenkel Joins Delfi Diagnostics as Chief Financial Officer
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, announced the appointment of Doug Schenkel as Chief Financial Officer.
Oct 7, 2021 | BioSpaceDelfi Diagnostics' tech shows early success in detecting 90% of lung cancer cases
A pair of studies by Baltimore's Delfi Diagnostics showed the company's tech was able to detect about 90% of lung cancer — one of the world's deadliest cancers — in a group of nearly 800 patients.
Aug 24, 2021 | Baltimore Business JournalDelfi Diagnostics partners with NYU Langone
Delfi also said that it has partnered with NYU Langone to investigate additional applications for the platform in specific populations, such as non-smoking Asian women, where improved early detection of lung cancer could reduce mortality but cancer screening is not currently recommended.
Mar 30, 2021 | genomeweb.comDelfi Diagnostics raises $100M for a new approach to screening blood for cancer
Delfi's technology employs machine learning to profile the entirety of genomes collected from the bloodstream—including DNA from healthy white blood cells, as well as strands shed by tumors—and compares the two to spot any changes.
Jan 13, 2021 | Fierce Biotech